Young Taek Han

Title: Young Taek Han and His Work on mTOR-Targeting Therapeutics.

Introduction

Young Taek Han is an inventor associated with Cheonan, South Korea, and Aliad Biopharma. His work includes research into compounds that inhibit the mTOR signaling pathway, which is implicated in nervous system disorders.

Latest Patents

Han is associated with 1 patent: “Composition for Preventing or Treating Nervous System Diseases Comprising Compound That Inhibits mTOR Signaling Pathway as Active Ingredient.” The invention describes a novel compound, a method for preparing it, and a pharmaceutical composition containing it. The compound was reported to inhibit mTORC1 and mTORC2, activate autophagy, and alleviate symptoms associated with Alzheimer’s-type dementia in animal models. The patent presents the compound as a potential treatment or preventive approach for nervous system diseases, including neurodegenerative diseases and mTORopathies.

Career Highlights

Han’s patent work focuses on translating findings about mTOR signaling and autophagy into a potential pharmaceutical application. The disclosed research connects the compound’s biological activity with outcomes observed in dementia model animals.

Collaborations

The information provided lists Hyockman Kwon and Yunhee Kim as Han’s coworkers. It does not specify their roles or contributions to the patent.

Conclusion

Young Taek Han’s patent work at Aliad Biopharma centers on a compound targeting mTOR signaling, with potential applications in preventing or treating nervous system diseases.